BUD
MCID: BRL010
MIFTS: 45

Buruli Ulcer (BUD)

Categories: Genetic diseases, Infectious diseases, Muscle diseases, Rare diseases, Skin diseases

Aliases & Classifications for Buruli Ulcer

MalaCards integrated aliases for Buruli Ulcer:

Name: Buruli Ulcer 57 73 20 54 44 17 70
Buruli Ulcer, Susceptibility to 57 29 13 6 39
Buruli Ulcer Disease 12 20 15
Mycobacterium Ulcerans, Susceptibility to 57
Mycobacterium Ulcerans 57
Bairnsdale Ulcer 12
Daintree Ulcer 12
Searle's Ulcer 12
Mossman Ulcer 12
Searl Ulcer 12
Bud 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0050456
OMIM® 57 610446
MeSH 44 D054312
NCIt 50 C84604
SNOMED-CT 67 186343005
ICD10 32 A31.1
UMLS 70 C0085568

Summaries for Buruli Ulcer

OMIM® : 57 Buruli ulcer is an infectious disease prevalent in many tropical and subtropical regions caused by infection with Mycobacterium ulcerans. It is the third most frequent mycobacterial disease in humans worldwide, after tuberculosis (607948) and leprosy (246300). Lesions are most common on exposed parts of the body, especially the limbs. Buruli ulcer derives its name from a county in Uganda, East Africa, north of Kampala, where the disease was found in the late 1950s in hundreds of people living near marshes and riverine areas near the Nile River (Clancey et al., 1961; Barker, 1971). The disease was first described in the medical literature in 1948 in a report on patients in Australia (MacCallum et al., 1948). Patients have also been reported from tropical areas in Latin America and Asia (Stienstra et al., 2006; van der Werf et al., 2005). (610446) (Updated 05-Apr-2021)

MalaCards based summary : Buruli Ulcer, also known as buruli ulcer, susceptibility to, is related to leprosy 3 and disease by infectious agent, and has symptoms including nodule An important gene associated with Buruli Ulcer is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Th2 Differentiation Pathway and IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. The drugs Rifampicin and Streptomycin have been mentioned in the context of this disorder. Affiliated tissues include skin, subcutaneous tissue and whole blood.

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin or located in subcutaneous tissue, has material basis in Mycobacterium ulcerans, which could be transmitted by insects. The bacterium produces a toxin, named mycolactone, which causes subcutaneous fat necrosis and inhibits an immune response. The infection has symptom nodule, which is a painless, mobile swelling in the skin.

Wikipedia : 73 Buruli ulcer (/bəˈruːli/) is an infectious disease characterized by the development of painless open... more...

Related Diseases for Buruli Ulcer

Diseases related to Buruli Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 394)
# Related Disease Score Top Affiliating Genes
1 leprosy 3 31.3 SLC11A1 IL10 IFNG
2 disease by infectious agent 31.0 SLC11A1 IL10 IFNG
3 bacterial infectious disease 30.5 SLC11A1 IL10 IFNG
4 cutaneous leishmaniasis 30.2 SLC11A1 IL10 IFNG
5 leishmaniasis 30.2 SLC11A1 IL10 IFNG
6 mycobacterium tuberculosis 1 30.2 SLC11A1 IL10 IFNG
7 leptospirosis 30.2 IL10 IFNG
8 lepromatous leprosy 30.2 IL10 IFNG
9 subacute sclerosing panencephalitis 29.8 IL10 IFNG
10 allergic bronchopulmonary aspergillosis 29.7 IL10 IFNG
11 invasive aspergillosis 29.7 IL10 IFNG
12 appendicitis 29.7 IL10 IFNG
13 pulmonary tuberculosis 29.6 SLC11A1 IL10 IFNG
14 gastrointestinal ulceration, recurrent, with dysfunctional platelets 11.4
15 renal hypodysplasia/aplasia 1 11.0
16 solitary median maxillary central incisor 10.9
17 incisors, fused mandibular 10.9
18 neuropathy, hereditary sensory and autonomic, type iia 10.9
19 tarp syndrome 10.9
20 skin disease 10.9
21 hansen's disease 10.8
22 osteomyelitis 10.6
23 mycobacterium marinum 10.5
24 polydactyly 10.4
25 hair whorl 10.4
26 squamous cell carcinoma 10.3
27 post-transplant lymphoproliferative disease 10.3 SLC11A1 IL10
28 triiodothyronine receptor auxiliary protein 10.2
29 wiskott-aldrich syndrome 10.2
30 chronic ulcer of skin 10.2
31 cytokine deficiency 10.2
32 trachoma 10.2 IL10 HBB
33 spotted fever 10.2 IL10 IFNG
34 spotted fever rickettsiosis 10.2 IL10 IFNG
35 chronic graft versus host disease 10.2 IL10 IFNG
36 pericardial tuberculosis 10.2 IL10 IFNG
37 orofacial granulomatosis 10.2 IL10 IFNG
38 eales disease 10.2 IL10 IFNG
39 nickel allergic contact dermatitis 10.2 IL10 IFNG
40 bronchiolitis 10.2
41 primary peritoneal carcinoma 10.2 IL10 IFNG
42 mansonelliasis 10.2 IL10 IFNG
43 tungiasis 10.2 IL10 IFNG
44 sporotrichosis 10.2 IL10 IFNG
45 iron metabolism disease 10.2 SLC11A1 HBB
46 baylisascariasis 10.2 IL10 IFNG
47 chronic active epstein-barr virus infection 10.2 IL10 IFNG
48 mucocutaneous leishmaniasis 10.2 IL10 IFNG
49 chorioretinitis 10.2 IL10 IFNG
50 clonorchiasis 10.2 IL10 IFNG

Graphical network of the top 20 diseases related to Buruli Ulcer:



Diseases related to Buruli Ulcer

Symptoms & Phenotypes for Buruli Ulcer

Clinical features from OMIM®:

610446 (Updated 05-Apr-2021)

Symptoms:

12
  • nodule

Drugs & Therapeutics for Buruli Ulcer

Drugs for Buruli Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifampicin Approved Phase 2, Phase 3 13292-46-1 5381226 5458213
2
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
3
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
4 Anti-Bacterial Agents Phase 2, Phase 3
5 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
6 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
7 Anti-Infective Agents Phase 2, Phase 3
8
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
9 Antimalarials Phase 2
10 Antiparasitic Agents Phase 2
11 Antiprotozoal Agents Phase 2
12 Antibiotics, Antitubercular

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
2 Randomised Trial for Early Lesions Caused by M. Ulcerans - Comparison Between 8 Weeks Streptomycin and Rifampicin (SR), or 4 Weeks SR Followed by 4 Weeks R Plus Clarithromycin Completed NCT00321178 Phase 2, Phase 3 SR4 - switch to CR4
3 Comparison of Early and Late Administration of Doxycycline in Their Efficacy Against Mansonella Perstans and in Development of Immunity Against Mycobacterial Infections Completed NCT02281643 Phase 2 Doxycycline
4 A Study of the Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer Unknown status NCT02153034
5 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
6 Timing of the Decision on Surgical Intervention for Buruli Ulcer Patients Treated With Rifampicin/Streptomycin Completed NCT01432925
7 Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHOrecommended Wound Management in West Africa Recruiting NCT03957447
8 Thermotherapy of Buruli Ulcer at Community Level in the Health District of Akonolinga Withdrawn NCT03969940

Search NIH Clinical Center for Buruli Ulcer

Cochrane evidence based reviews: buruli ulcer

Genetic Tests for Buruli Ulcer

Genetic tests related to Buruli Ulcer:

# Genetic test Affiliating Genes
1 Buruli Ulcer, Susceptibility to 29 SLC11A1

Anatomical Context for Buruli Ulcer

The Foundational Model of Anatomy Ontology organs/tissues related to Buruli Ulcer:

19
Skin, Subcutaneous Tissue

MalaCards organs/tissues related to Buruli Ulcer:

40
Skin, Whole Blood, Skeletal Muscle, Colon, Breast, Endothelial

Publications for Buruli Ulcer

Articles related to Buruli Ulcer:

(show top 50) (show all 978)
# Title Authors PMID Year
1
Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. 54 61 6 57
16395392 2006
2
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 57 61
24949969 2014
3
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. 61 57
23549080 2013
4
Mycobacterium ulcerans disease. 57 61
16283056 2005
5
Mycolactone subverts immunity by selectively blocking the Sec61 translocon. 57
27821549 2016
6
Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. 57
9486992 1998
7
Buruli disease in a district of Uganda. 57
5143865 1971
8
A new mycobacterial infection in man. 57
18876541 1948
9
Genetic variants in human BCL2L11 (BIM) are associated with ulcerative forms of Buruli ulcer. 61
33467983 2021
10
Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans. 61
33777679 2021
11
Mapping suitability for Buruli ulcer at fine spatial scales across Africa: A modelling study. 61
33657104 2021
12
Reconstructive surgery for sequellae of Mycobacterium ulcerans infection (Buruli ulcer) of the upper limb. 61
33645421 2021
13
Genetics in the Host-Mycobacterium ulceransm ulcerans interaction. 61
33682158 2021
14
The cell surface protein MUL_3720 confers binding of the skin pathogen Mycobacterium ulcerans to sulfated glycans and keratin. 61
33630844 2021
15
Investigation of skin microbiota reveals Mycobacterium ulcerans-Aspergillus sp. trans-kingdom communication. 61
33580189 2021
16
Immunity against Mycobacterium ulcerans: The subversive role of mycolactone. 61
33607704 2021
17
Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine. 61
33371993 2021
18
In vitro Anti-Mycobacterium ulcerans and cytotoxic activities of some selected medicinal plants and an indoloquinoline alkaloid. 61
33707373 2021
19
Treatment outcomes of drug susceptible Tuberculosis in private health facilities in Lagos, South-West Nigeria. 61
33471851 2021
20
Novel Diagnostics for Kaposi Sarcoma and Other Skin Diseases in Resource-Limited Settings. 61
33228864 2021
21
Buruli ulcer in a traveller returning from Madagascar: the first report of Mycobacterium ulcerans infection from the region. 61
33063113 2021
22
Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions. 61
33402095 2021
23
Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology. 61
33338061 2020
24
Etymologia: Buruli Ulcer. 61
33220026 2020
25
Mobile Health Strategies to Tackle Skin Neglected Tropical Diseases With Recommendations From Innovative Experiences: Systematic Review. 61
33382382 2020
26
The diversity of mycolactone-producing mycobacteria. 61
32702376 2020
27
Impact of mycolactone produced by Mycobacterium ulcerans on life-history traits of Aedes aegypti (L.) and resulting habitat selection for oviposition. 61
33612750 2020
28
Spatiotemporal analysis of mycolactone distribution in vivo reveals partial diffusion in the central nervous system. 61
33264290 2020
29
Coexistence of Mycobacterium ulcerans ssp. shinshuense and Mycobacterium avium in a patient with Buruli ulcer-compatible lesions. 61
32881049 2020
30
Buruli ulcer: a new case definition for Victoria. 61
33349204 2020
31
Buruli ulcer and Mycobacterium ulcerans. 61
32129872 2020
32
Mycolactone induces cell death by SETD1B-dependent degradation of glutathione. 61
33006969 2020
33
Introduction of Mycobacterium ulcerans disease in the Bankim Health District of Cameroon follows damming of the Mapé River. 61
32886658 2020
34
Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. 61
32866170 2020
35
Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer. 61
32571813 2020
36
Toward a Single-Dose Cure for Buruli Ulcer. 61
32631818 2020
37
Experiences of Buruli Ulcer Patients Following Discharge in the Greater Accra Region of Ghana. 61
32856525 2020
38
The co-infection of Buruli ulcer and cutaneous leishmaniasis in Sudanese patient: An association by choice or by chance? 61
32359927 2020
39
Variations in temperatures and the incidence of Buruli ulcer in Africa. 61
31513925 2020
40
Proteomics of Select Neglected Tropical Diseases. 61
32109150 2020
41
Histological and quantitative polymerase chain reaction-based analysis of Buruli ulcer using mapping biopsy method. 61
32569298 2020
42
The immunology of other mycobacteria: M. ulcerans, M. leprae. 61
32100087 2020
43
Human genetics of Buruli ulcer. 61
32266523 2020
44
Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans. 61
32589646 2020
45
Tracing Mycobacterium ulcerans along an alimentary chain in Côte d'Ivoire: A one health perspective. 61
32463813 2020
46
Impact of common skin diseases on children in rural Côte d'Ivoire with leprosy and Buruli ulcer co-endemicity: A mixed methods study. 61
32421709 2020
47
Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana. 61
32453800 2020
48
Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. 61
32205344 2020
49
Individual and clinical variables associated with the risk of Buruli ulcer acquisition: A systematic review and meta-analysis. 61
32267838 2020
50
Does skin surface temperature variation account for Buruli ulcer lesion distribution? 61
32310955 2020

Variations for Buruli Ulcer

ClinVar genetic disease variations for Buruli Ulcer:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SLC11A1 NM_000578.4(SLC11A1):c.1627G>A (p.Asp543Asn) SNV risk factor 9233 rs17235409 GRCh37: 2:219259732-219259732
GRCh38: 2:218395009-218395009

Expression for Buruli Ulcer

Search GEO for disease gene expression data for Buruli Ulcer.

Pathways for Buruli Ulcer

GO Terms for Buruli Ulcer

Biological processes related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of phagocytosis GO:0050766 9.46 SLC11A1 IFNG
2 interleukin-12-mediated signaling pathway GO:0035722 9.43 IL10 IFNG
3 positive regulation of nitric oxide biosynthetic process GO:0045429 9.4 IFNG HBB
4 negative regulation of cytokine production GO:0001818 9.37 SLC11A1 IL10
5 response to interferon-gamma GO:0034341 9.32 SLC11A1 SEC61A1
6 defense response to protozoan GO:0042832 9.26 SLC11A1 IL10
7 positive regulation of signaling receptor activity GO:2000273 9.16 IL10 IFNG
8 positive regulation of MHC class II biosynthetic process GO:0045348 8.96 IL10 IFNG
9 positive regulation of cytokine production GO:0001819 8.8 SLC11A1 IL10 IFNG

Sources for Buruli Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....